The Lynx Group
Cholangiocarcinoma News

Final Results of ClarIDHy Trial of Ivosidenib in Patients with Previously Treated CCA Harboring an IDH1 Mutation

2021 Year in Review: Cholangiocarcinoma — December 17, 2021

Final results of the ClarIDHy trial demonstrated the clinical benefit of ivosidenib in patients with previously treated unresectable or metastatic CCA harboring an IDH1 mutation.

The global, phase 3, multicenter, randomized, double-blind ClarIDHy study (ClinicalTrials.gov Identifier: NCT02989857) compared the first-in-class, oral, small-molecule inhibitor of mutant IDH1 ivosidenib with placebo in patients with previously treated unresectable or advanced cholangiocarcinoma (CCA) who harbor IDH1 mutations. Final results of the ClarIDHy study were presented at the 2021 American Society of Clinical Oncology Gastrointestinal Cancers Annual Meeting.

In the ClarIDHy study, eligibility criteria included unresectable or metastatic CCA, centrally confirmed IDH1 mutations by next-generation sequencing, Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1; measurable disease (RECIST version 1.1), and 1 or 2 prior therapies. Eligible patients were randomized in a 2:1 ratio to receive ivosidenib (500 mg once daily in continuous 28-day cycles) or placebo. Stratification was by number of prior systemic therapies (1 or 2). The study design allowed crossover from placebo to ivosidenib upon radiographic disease progression. The primary end point was progression-free survival (PFS) by blinded independent radiology center (IRC). Secondary end points included overall survival (OS), objective response rate, investigator-assessed PFS, safety, and health-related quality of life (HRQOL). Since crossover may confound estimates of survival, rank-preserving structural failure time (RPSFT) was applied to adjust for crossover in the trial. The data cutoff was May 31, 2020.

A total of 187 eligible patients were randomized to receive ivosidenib (n = 126) or placebo (n = 61). The median age of the study population was 62 years. The majority of the participants were female, had intrahepatic CCA (91%), and had metastatic disease (93%). Overall, 47% of the patients had received 2 prior therapies. The majority of patients receiving placebo (70.5%) crossed over to open-label ivosidenib upon radiographic disease progression and unblinding, as permitted by the study protocol. At data cutoff, 25 (15.1%) patients remained on ivosidenib for ≥1 years, including 6 crossover patients.

The primary end point was met with significant improvement in PFS by IRC with ivosidenib versus placebo (hazard ratio [HR], 0.37; 95% confidence interval [CI], 0.25-0.54; P <.0001), which extended across all prespecified subgroups tested, including sex, prior lines of therapy, extent of disease at screening, cancer type at initial diagnosis, and ECOG PS. The disease control rate was 53% with ivosidenib versus 28% with placebo.

OS analysis, following 79% OS events in the ivosidenib arm and 82% in the placebo arm, showed a favorable trend for improved OS with ivosidenib treatment versus placebo (median OS, 10.3 vs 7.5 months, respectively; HR, 0.79; 95% CI, 0.56-1.12; one-sided P = .093). After accounting for crossover, the RPSFT-adjusted median OS was 5.1 months with placebo (HR, 0.49; 95% CI, 0.34-0.70; P <.0001).

Common all-grade ivosidenib treatment-emergent adverse events (TEAEs) that occurred in ≥15% of the patients included nausea (41.5%), diarrhea (35.0%), fatigue (30.9%), cough (25.2%), abdominal pain (24.4%), decreased appetite (24.4%), ascites (22.8%), vomiting (22.8%), and anemia (17.9%). A higher proportion of patients in the ivosidenib cohort, compared with the placebo cohort, experienced grade ≥3 TEAEs (53.0% vs 37.3%, respectively). The most common grade ≥3 TEAEs associated with ivosidenib therapy included ascites (9.0%), anemia (7.2%), and increased blood bilirubin (5.4%). No treatment-related deaths were reported. Treatment discontinuation due to adverse events occurred more frequently in the placebo arm than in the ivosidenib arm (8.5% vs 6.6%, respectively).

Compared with those in the placebo group, ivosidenib-treated patients preserved HRQOL physical functioning subscale and pain subscales. Patients in the ivosidenib cohort experienced significantly less decline in physical and emotional functioning domains of quality of life at cycle 2, day 1, compared with those in the placebo group (nominal P <.05).

The final results of the ClarIDHy trial demonstrated the clinical benefit of ivosidenib in patients with previously treated, unresectable or metastatic CCA who harbor an IDH1 mutation in terms of PFS, safety, and HRQOL, demonstrating a favorable OS trend despite a high rate of crossover.

These results were recently published, and on August 25, 2021, the US Food and Drug Administration (FDA) approved ivosidenib for adult patients with previously treated, locally advanced or metastatic CCA with an IDH1 mutation, as detected by an FDA-approved test.

Sources: Abou-Alfa GK, Macarulla T, Javle MM, et al. Final results from ClarIDHy, a global, phase 3, randomized, double-blind study of ivosidenib (IVO) versus placebo (PBO) in patients (pts) with previously treated cholangiocarcinoma (CCA) and an isocitrate dehydrogenase 1 (IDH1) mutation. J Clin Oncol. 2021;39(suppl_15):4069-4069.

Zhu AX, Macarulla T, Javle MM, et al. Final overall results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: the phase 3 randomized clinical ClarIDHy trial. JAMA Oncol. 2021;7:1669-1677.

Related Items

Phase 1 Results of Gunagratinib in Patients with Advanced Solid Tumors Harboring FGFR Pathway Alterations
2021 Year in Review: Cholangiocarcinoma
A phase 1/2a, first-in-human clinical study demonstrated that the highly selective, irreversible pan-FGFR inhibitor gunagratinib was safe and well-tolerated in patients with advanced solid tumors, including CCA.
Prognostic Value of FGFR2 Alterations in Patients Receiving Systemic Chemotherapy for Intrahepatic CCA
2021 Year in Review: Cholangiocarcinoma
A retrospective analysis indicated the prognostic value of FGFR2 fusions/rearrangements in patients with intrahepatic CCA receiving systemic chemotherapy, which warrants additional study.
FGFR2 Fusion and/or Rearrangement Profiling in Chinese Patients with Intrahepatic CCA
2021 Year in Review: Cholangiocarcinoma
Epidemiologic data assessed the incidence rate of FGFR2 gene fusion or rearrangement in Chinese patients with intrahepatic CCA, including those with heterogeneous FGFR2 partner genes.
A Comprehensive Genomic and Immune Profiling Study of IDH1- and IDH2-Driven Intrahepatic CCA
2021 Year in Review: Cholangiocarcinoma
A comprehensive genomic and immune characterization of IDH-mutated and wild-type intrahepatic CCA revealed significant differences in genetic alterations.
Characteristics of IDH Mutations in Bile Duct Carcinoma in a Chinese Population
2021 Year in Review: Cholangiocarcinoma
A retrospective analysis in a large Chinese patient cohort with bile duct carcinoma indicated that activating IDH1/2 mutations occurred at a lower rate compared with that previously reported in the global population.
Silmitasertib (CX-4945) plus Gemcitabine and Cisplatin as First-Line Treatment for Patients with Locally Advanced or Metastatic CCA
2021 Year in Review: Cholangiocarcinoma
Preliminary evidence suggests that combination treatment with silmitasertib plus gemcitabine/cisplatin as first-line therapy has promising efficacy and a favorable safety profile in patients with locally advanced or metastatic CCA.
Targeted Therapies in CCA: Assessment of US Oncologist Practice Patterns
2021 Year in Review: Cholangiocarcinoma
Findings from a clinical practice assessment identified gaps in knowledge, competence, and confidence regarding testing and the use of targeted therapies in patients with unresectable CCA, underscoring the important role of education in overcoming these gaps.
First-Line Toripalimab plus Lenvatinib in Combination with GemOx Chemotherapy for Advanced Intrahepatic CCA
2021 Year in Review: Cholangiocarcinoma
Results of a phase 2 study indicate that toripalimab and lenvatinib in combination with GemOx chemotherapy provide antitumor activity and reasonable tolerability in patients with advanced intrahepatic CCA.
Comparative Landscape of Actionable Somatic Alterations in Advanced CCA from Circulating Tumor and Tissue-Based DNA Profiling
2021 Year in Review: Cholangiocarcinoma
Findings from a retrospective analysis support the use of both tissue and liquid biopsy biomarker testing to guide therapy selection in patients with advanced CCA, particularly when tissue may not be readily available.
Tibsovo (Ivosidenib) FDA Approved for Advanced or Metastatic Cholangiocarcinoma and IDH1 Mutation
By Loretta Fala
2021 Year in Review: Cholangiocarcinoma
Cholangiocarcinoma (CCA) is an aggressive cancer of the bile duct that forms inside the liver (ie, intrahepatic) or outside the liver (ie, extrahepatic, including perihilar and distal tumors). Individuals with colitis or certain liver diseases may have an increased risk for CCA. Although the precise incidence of CCA is unknown, an estimated 8000 new cases of CCA are diagnosed annually in the United States. It is likely, however, that this number is higher, because CCA is difficult to diagnose and may be misclassified at times.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: